Clinical trials
Observational Heart Diseases trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 6 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| China National Center for Cardiovascular Diseases | 3 |
| Chongqing Medical University | 2 |
| Changchun University of Chinese Medicine | 1 |
| Edwards Lifesciences | 1 |
| Fu Wai Hospital, Beijing, China | 1 |
| Henan Institute of Cardiovascular Epidemiology | 1 |
| JW Medical Systems Ltd | 1 |
| Lian Yang | 1 |
| Medtronic Cardiac Rhythm and Heart Failure | 1 |
| North Sichuan Medical College | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Diseases | 18 |
| Cardiovascular Diseases | 9 |
| Coronary Artery Disease | 6 |
| Arteriosclerosis | 5 |
| Vascular Diseases | 5 |
| Coronary Disease | 4 |
| Myocardial Ischemia | 4 |
| Arterial Occlusive Diseases | 3 |
| Hypertension | 3 |
| Angina Pectoris | 2 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.